Efficacy and Safety of Deucravacitinib in Moderate to Severe IBD: Phase 2 Trial Results

Overview

Three phase 2 randomized, double-blind, placebo-controlled trials evaluated deucravacitinib, a selective TYK2 inhibitor, in patients with moderately to severely active Crohn’s disease and ulcerative colitis. The studies did not meet their primary efficacy endpoints, with high placebo response rates observed. Deucravacitinib was well tolerated with a safety profile consistent with prior psoriasis studies and no new safety signals.

Background

Inflammatory bowel disease (IBD), comprising Crohn’s disease (CD) and ulcerative colitis (UC), involves chronic gastrointestinal inflammation driven by complex genetic and immunologic factors. Current biologic therapies achieve remission in only 18%–48% of patients, highlighting the need for novel treatments. IL-23 is a key cytokine in IBD pathogenesis, and TYK2 mediates IL-23 signaling intracellularly. Deucravacitinib is an oral, selective allosteric TYK2 inhibitor approved for psoriasis, with a differentiated safety profile compared to JAK inhibitors. Preclinical models suggested potential efficacy in IBD, prompting clinical evaluation.

Data Highlights

Key Findings

• Deucravacitinib did not demonstrate statistically significant clinical benefit over placebo in moderately to severely active Crohn’s disease or ulcerative colitis across all three phase 2 trials.
• High placebo response rates were observed throughout the studies, complicating efficacy assessments.
• The safety profile of deucravacitinib was consistent with that seen in psoriasis patients, with no new safety concerns identified.
• Deucravacitinib’s selective allosteric inhibition of TYK2 differentiates it from broader JAK inhibitors, potentially contributing to its favorable safety profile.
• Early termination of LATTICE-CD and IM011-127 trials occurred due to lack of efficacy.

Clinical Implications

Although deucravacitinib was safe and well tolerated, its lack of efficacy in these phase 2 trials suggests it is not effective as an induction therapy for moderate to severe Crohn’s disease or ulcerative colitis. The high placebo response rates highlight challenges in clinical trial design for IBD. Further research may be needed to explore alternative dosing, combination therapies, or patient subgroups that could benefit from TYK2 inhibition.

Conclusion

Deucravacitinib, despite a favorable safety profile, did not achieve significant clinical efficacy in moderate to severe IBD in these phase 2 studies. These findings underscore the complexity of targeting TYK2 in IBD and the need for continued therapeutic innovation.

References

1. LATTICE-CD, LATTICE-UC, IM011-127 Phase 2 Trials -- Deucravacitinib in IBD